Neurocritical Care News

No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.

Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

Concussions suffered in hockey led to substantial missed playing time, while their physical effects require leagues of all ages to bolster rules, utilize protective equipment and implement high-quality injury protocols to address the issue.

Published results showed gender may not be a significant factor in return to learn rates for high school athletes with sports-related concussions.

Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.

Published results showed an investigational head and neck cooling device reduced symptom severity for adolescent athletes with a sports-related concussion compared with standard post-concussion care alone.

NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.